Recent changes
GovPing tracks 141 sources for this role out of 2,348 total sources on GovPing, covering Guidance, Enforcement, Rule, Notice, and Consultation instruments. There were 722 changes in the last 7 days.
Health Canada issued a Type I recall for nitrous oxide chargers sold by DOODELZ, Gold Whip, and Whip-it! brands without market authorization, while the UK VMD called for a Class II recall of Zoetis's Scabigard Suspension for cutaneous administration. FDA classified Draeger's Atlan A350 anesthesia workstations as a Class I recall due to potential piston ventilator failure, and Morovan recalled approximately 4,000 units of Gel Nail Polish Remover for methylene chloride and chloroform contamination.
Benzo nitrogen-containing heteroaromatic ring derivative for complement factor B treatment
The USPTO granted patent US12595270B2 to Xizang Haisco Pharmaceutical Co., Ltd. covering a benzo nitrogen-containing heteroaromatic ring derivative (general formula I) and its use in treating diseases associated with complement factor B activity or expression. The patent includes 8 claims encompassing the compound, stereoisomers, deuterates, solvates, prodrugs, metabolites, and pharmaceutically acceptable salts or co-crystals.
Amide EZH2 Inhibitor Patent - Preparation Method and Medical Applications
The USPTO granted patent US12595267B2 to Shanghai Synergy Pharmaceutical Sciences Co., Ltd. covering an amide small molecule compound that inhibits EZH2 (Zeste gene enhancer homolog 2). The patent protects methods for preparing the compound and its use in treating EZH2-mediated diseases including tumors, myeloproliferative diseases, and autoimmune diseases. The patent contains 11 claims and names 19 inventors.
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
Syngenta patent 12595266B2, pesticide sulfur compounds, Apr 07
Acid anhydride compound, polyamideimide resin and film
USPTO granted Patent US12595268B2 to Korea Advanced Institute of Science and Technology (KAIST) for a novel acid anhydride compound and polyamideimide resin and film utilizing the same. The invention provides high thermal resistance, low coefficient of thermal expansion, and colorless transparency properties. The patent contains 11 claims and was filed under Application No. 18517326.
Monoclonal antibody matrix metalloproteinase-1 patent granted
USPTO granted Patent US12595315B2 to S&T BIOMED CO., LTD. for a monoclonal antibody specific to matrix metalloproteinase-1. The patent covers the antibody's heavy and light chain variable regions with specific CDR sequences, along with polynucleotides, detection kits, and detection methods. This grant date is April 7, 2026.
GPC3 antibody patent - methods of use for cancer treatment
The USPTO granted patent US12595314B2 to R.P. Scherer Technologies, LLC for antibodies specific to glypican-3 (GPC3). The patent covers 37 claims including the antibody compositions, nucleic acids encoding the antibodies, methods of manufacturing, and therapeutic uses for treating cell proliferative disorders by enhancing immune responses such as T cell responses to cancer cells.
CLDN18.2 binding molecule patent granted to Sanyou
CLDN18.2 binding molecule patent granted to Sanyou
TfR1 Humanized Antibodies and Cancer Treatment Methods
The USPTO issued Patent US12595310B2 to The Regents of the University of California covering transferrin receptor 1 (TfR1)-binding proteins, including humanized antibodies and methods for treating cancer. The patent, granted on April 7, 2026, includes 20 claims and was filed on November 6, 2020 under Application No. 17775167. The invention relates to humanized TfR1-binding proteins with amino acid substitutions, combination treatments with additional therapeutics, and methods for cancer therapy.
Means and methods for detecting soy allergens
The USPTO granted Patent US12596111B2 to Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. covering methods for manufacturing antibodies that specifically bind to soy Gly m 8 protein and methods for detecting soy material in food or feedstuff preparations using said antibodies. The patent includes 12 claims and covers antibody production via plant-based protein expression, particularly in tobacco plants.
IGF-1R Antibody Compositions for Treatment of Thyroid Eye Disease
The USPTO granted Patent US12595309B2 to Viridian Therapeutics, Inc. covering insulin-like growth factor-1 receptor (IGF-1R) antibody compositions and methods for treating thyroid eye disease (TED). The patent includes 23 claims directed to pharmaceutical compositions and methods of reducing proptosis and Clinical Activity Score (CAS) by inhibiting IGF-1R activity. The patent claims priority to Application No. 18942051, filed November 8, 2024.
Get daily alerts for pharma & life sciences
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
620 changes in last 7 days
Latest high priority updates
142 official sources tracked
Frequently asked questions
What does this feed cover?
FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.
Who is this for?
Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.
How often is this updated?
GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.
Does this cover EMA and international regulators?
Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.
How is this different from AgencyIQ?
AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.
Is GovPing free?
Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.
Need to monitor something else?
GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.
Get Pharma & Life Sciences alerts
Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.
Free. Unsubscribe anytime.